{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:40Z","timestamp":1786985800802,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ccell.2020.04.013","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T10:43:02Z","timestamp":1590057782000},"page":"850-866.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity"],"prefix":"10.1016","volume":"37","author":[{"given":"Xiaojie","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T. Claude","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Penfold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Inzhelevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ian","family":"Mockridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Duriez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon R.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikki","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Sjef","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Tews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Glennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2020.04.013_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ni792","article-title":"The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells","volume":"3","author":"Ahonen","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.str.2019.10.011","article-title":"Modeling antibody-antigen complexes by information-driven docking","volume":"28","author":"Ambrosetti","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.ccell.2020.04.013_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.2130","article-title":"Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis","volume":"39","author":"Anil Kumar","year":"2018","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ccell.2020.04.013_bib4","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.iy.12.040194.004313","article-title":"The CD40 antigen and its ligand","volume":"12","author":"Banchereau","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2015-09-625343","article-title":"Influence of immunoglobulin isotype on therapeutic antibody function","volume":"127","author":"Beers","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.04.013_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.04.013_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-05-2856","article-title":"The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma","volume":"66","author":"Bevaart","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib9","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.immuni.2011.11.009","article-title":"Monocyte subsets responsible for immunoglobulin G-dependent effector functions in\u00a0vivo","volume":"35","author":"Biburger","year":"2011","journal-title":"Immunity"},{"issue":"14 Suppl","key":"10.1016\/j.ccell.2020.04.013_bib10","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1158\/1538-7445.AM2016-5004","article-title":"APX005M, a humanized anti-CD40 antibody with strong immune-modulatory activities capable of tumor eradication in\u00a0vivo. [abstract]","volume":"76","author":"Bj\u00f6rck","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib11","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI24772","article-title":"Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions","volume":"115","author":"Boruchov","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2020.04.013_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2020.04.013_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.04.013_bib14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2012-01-402370","article-title":"Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells","volume":"120","author":"Chatterjee","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.04.013_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T\u00a0cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcgammaR engagement","volume":"29","author":"Dahan","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.ccell.2020.04.013_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20062545","article-title":"Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program","volume":"204","author":"Dhodapkar","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib19","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IgG2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2020.04.013_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/eji.201847924","article-title":"Human Fcgamma receptors compete for TGN1412 binding that determines the antibody's effector function","volume":"49","author":"Dudek","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"issue":"Suppl. 3","key":"10.1016\/j.ccell.2020.04.013_bib22","first-page":"632","article-title":"CNI-free therapy with iscalimab (anti-CD40 mAb) preserves allograft histology compared to standard of care after kidney transplantation [abstract]","volume":"19","author":"Farkash","year":"2019","journal-title":"Am. J. Transplant."},{"issue":"Suppl. 10","key":"10.1016\/j.ccell.2020.04.013_bib23","first-page":"1784","article-title":"The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren\u2019s syndrome: a phase IIa double-blind, placebo-controlled randomized trial [abstract]","volume":"69","author":"Fisher","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ccell.2020.04.013_bib24","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.4049\/jimmunol.1700429","article-title":"A restricted role for FcgammaR in the regulation of adaptive immunity","volume":"200","author":"Fransen","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T\u00a0cells in\u00a0vivo","volume":"192","author":"den Haan","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib27","first-page":"159","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label study","volume":"17","author":"Harland","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ccell.2020.04.013_bib28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20171440","article-title":"Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity","volume":"215","author":"Hoves","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.tp.0000286058.79448.c7","article-title":"A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys","volume":"84","author":"Imai","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.ccell.2020.04.013_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ccell.2020.04.013_bib31","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib32","article-title":"OR19-6 A novel anti-CD40 monoclonal antibody, iscalimab, successfully treats Graves\u2019 hyperthyroidism","volume":"3","author":"Kahaly","year":"2019","journal-title":"J.\u00a0Endocr. Soc."},{"key":"10.1016\/j.ccell.2020.04.013_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ccell.2020.04.013_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ccell.2020.04.013_bib35","doi-asserted-by":"crossref","first-page":"10811","DOI":"10.1073\/pnas.191371898","article-title":"CD40 stimulation accelerates deletion of tumor-specific CD8(+) T\u00a0cells in the absence of tumor-antigen vaccination","volume":"98","author":"Kedl","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.04.013_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ccell.2020.04.013_bib37","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib38","doi-asserted-by":"crossref","first-page":"W225","DOI":"10.1093\/nar\/gkv309","article-title":"WAXSiS: a web server for the calculation of SAXS\/WAXS curves based on explicit-solvent molecular dynamics","volume":"43","author":"Knight","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib39","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1073\/pnas.1810566115","article-title":"Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity","volume":"115","author":"Knorr","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.04.013_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T\u00a0cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/cells8080927","article-title":"Targeting the CD40-CD154 signaling pathway for treatment of autoimmune arthritis","volume":"8","author":"Lai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ccell.2020.04.013_bib42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0952-7915(97)80043-X","article-title":"The CD40 pathway in allograft rejection, acceptance, and tolerance","volume":"9","author":"Larsen","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib43","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.04.013_bib44","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1073\/pnas.1319502110","article-title":"Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in\u00a0vivo","volume":"110","author":"Li","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.04.013_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1160\/TH09-01-0029","article-title":"The multi-functionality of CD40L and its receptor CD40 in atherosclerosis","volume":"102","author":"Lievens","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ccell.2020.04.013_bib46","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib47","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs","volume":"190","author":"Lux","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.celrep.2014.02.041","article-title":"A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity","volume":"7","author":"Lux","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2020.04.013_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The role of CD40 and CD154\/CD40L in dendritic cells","volume":"21","author":"Ma","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib50","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1021\/bi800576c","article-title":"Disulfide connectivity of human immunoglobulin G2 structural isoforms","volume":"47","author":"Martinez","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccell.2020.04.013_bib51","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible activation of MyD88 and CD40 in CAR T\u00a0cells results in controllable and potent antitumor activity in preclinical solid tumor models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.04.013_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib53","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1073\/pnas.082107699","article-title":"CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity","volume":"99","author":"van Mierlo","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.04.013_bib54","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.04.013_bib55","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","article-title":"Introduction of soluble protein into the class I pathway of antigen processing and presentation","volume":"54","author":"Moore","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib56","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib57","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1158\/0008-5472.CAN-16-2141","article-title":"Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor","volume":"76","author":"Ngiow","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","article-title":"Fcgamma receptors: old friends and new family members","volume":"24","author":"Nimmerjahn","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2020.04.013_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib60","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.1014515107","article-title":"FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in\u00a0vivo","volume":"107","author":"Nimmerjahn","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"13 Suppl","key":"10.1016\/j.ccell.2020.04.013_bib61","article-title":"A phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients [abstract]","volume":"79","author":"O'Hara","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib62","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/j.1600-6143.2012.04014.x","article-title":"Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates","volume":"12","author":"Oura","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ccell.2020.04.013_bib63","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/eji.201646795","article-title":"Regulation of immune cell signaling by SHIP1: a phosphatase, scaffold protein, and potential therapeutic target","volume":"47","author":"Pauls","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib64","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1084\/jem.20171435","article-title":"Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity","volume":"215","author":"Perry","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/imt.15.1","article-title":"Novel insights into anti-CD40\/CD154 immunotherapy in transplant tolerance","volume":"7","author":"Pinelli","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ccell.2020.04.013_bib67","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.4049\/jimmunol.166.9.5327","article-title":"Cutting edge: intravenous soluble antigen is presented to CD4 T\u00a0cells by CD8- dendritic cells, but cross-presented to CD8 T\u00a0cells by CD8+ dendritic cells","volume":"166","author":"Pooley","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2326-6066.CIR-13-0152","article-title":"Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer","volume":"2","author":"Richman","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib69","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"issue":"13 Suppl","key":"10.1016\/j.ccell.2020.04.013_bib70","article-title":"Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin\u00aemolecule for tumor-localized immune activation [abstract]","volume":"79","author":"Rigamonti","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in\u00a0vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib72","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"179","author":"Sallusto","year":"1994","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib73","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.04.013_bib74","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2015.00529","article-title":"The contribution of CD40\/CD40L axis in inflammatory bowel disease: an update","volume":"6","author":"Senhaji","year":"2015","journal-title":"Front Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib76","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1500078","article-title":"Human anti-CD40 antibody and poly IC:LC adjuvant combination induces potent T\u00a0cell responses in the lung of nonhuman primates","volume":"195","author":"Thompson","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-1759(00)00349-5","article-title":"CD40 ligation for immunotherapy of solid tumours","volume":"248","author":"Todryk","year":"2001","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ccell.2020.04.013_bib78","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.168.6.2720","article-title":"T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody","volume":"168","author":"Tutt","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib79","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.ccell.2020.04.013_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2013-04-490821","article-title":"Inhibitory FcgammaRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity","volume":"123","author":"Vaughan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.04.013_bib81","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol."},{"issue":"Suppl. 10","key":"10.1016\/j.ccell.2020.04.013_bib82","first-page":"1588","article-title":"Treatment with BI 655064 (antagonistic anti-CD40 antibody) modulates clinical and biomarker parameters associated with rheumatoid arthritis (RA) [abstract]","volume":"68","author":"Visvanathan","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ccell.2020.04.013_bib83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00262-018-2267-0","article-title":"Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy","volume":"68","author":"Vitale","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2020.04.013_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ccell.2020.04.013_bib85","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib86","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.04.013_bib87","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","article-title":"The TNF receptor superfamily in co-stimulating and co-inhibitory responses","volume":"44","author":"Ward-Kavanagh","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2020.04.013_bib88","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ajt.12330","article-title":"ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet\u00a0allograft survival in nonhuman primates","volume":"13","author":"Watanabe","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ccell.2020.04.013_bib89","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib90","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2020.04.013_bib91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"White","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib92","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1158\/2326-6066.CIR-17-0258","article-title":"Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity","volume":"5","author":"Wiehagen","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib93","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.ccell.2020.04.013_bib94","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/2326-6066.CIR-18-0805","article-title":"A bispecific molecule targeting CD40 and tumor antigen mesothelin enhances tumor-specific immunity","volume":"7","author":"Ye","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2020.04.013_bib95","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccell.2018.02.009","article-title":"Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.04.013_bib96","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","article-title":"The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes","volume":"428","author":"van Zundert","year":"2016","journal-title":"J.\u00a0Mol. Biol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820302129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820302129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:04:50Z","timestamp":1761523490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610820302129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1535610820302129"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2020.04.013","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2020.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}